Fluvoxamine as a Treatment for COVID-19 - Frankly Speaking Ep 265
Pri-Med Podcasts
English - February 28, 2022 00:30 - 12 minutes - 11.4 MB - ★★★★★ - 71 ratingsLife Sciences Science Health & Fitness education faq medical primed Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: COVID-19 and Children - Frankly Speaking Ep 264
Credits: 0.25 AMA PRA Category 1 Credit™
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-265
Overview: Most cases of COVID-19 will resolve without interventions, but some patients are at high risk for complications. Several treatment options for high-risk patients are now available to help prevent the need for hospitalization. Join us to review a recent large, randomized trial evaluating fluvoxamine as a treatment for high-risk patients who were diagnosed with COVID-19.
Episode resource links:
Reis G, et al. TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022 Jan;10(1):e42-e51
Berwanger O. Fluvoxamine for outpatients with COVID-19: where do we stand? Lancet Glob Health. 2022 Jan;10(1):e2-e3. doi: 10.1016/S2214-109X(21)00501-5
https://activ6study.org/
Guest: Alan M. Ehrlich, MD, FAAFP
Music Credit: Richard Onorato